Latest filing published 20 Apr 2026 for KalVista Pharmaceuticals, Inc., €32k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Nicole Sweeny, listed as senior executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in KalVista Pharmaceuticals, Inc. and Praxis Precision Medicines, Inc. The record holds 18 filings, for trades running from 12 February 2021 to 17 April 2026.
On the market, this insider has only sold: 5 sales, €167k in total. Other entries cover 6 share grants and 7 option exercises. Since January 2026: no purchases and 2 sales on the market.
The latest filing, published on 20 April 2026, reports an open-market sale of €32k in KalVista Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations